The rise of virtual pharma
The rise of virtual business models in biopharma reflects the changing face of the pharmaceutical industry - big pharma discovering and developing its own pipeline exclusively in-house no longer exists.
11th February 2019
Web Exclusives
Medical devices regulation countdown
Cliodhna McDonough says new regulations on the horizon for medical devices in Europe present a huge challenge to manufacturers, but could also deliver improved confidence in the consistency and effectiveness of the regulatory process.
11th February 2019
The SPC eligibility issue
The European Court should prepare for legal challenges to the ineligibility of new medical technologies for Supplementary Protection Certificates (SPCs).
23rd January 2019
Redefining Value
In today’s highly competitive healthcare market how can pharma companies stand out from the crowd? Showing brand value has never been more important.
23rd January 2019
The controversy over gene-editing
CRISPR has the potential to transform a variety of scientific areas, but this genome editing technique is also shrouded in controversy, particularly regarding its potential use to create genetically engineered humans.
10th January 2019
Unlocking sci-tech growth in the UK
The health of the life sciences sector in 2019 will continue to be a major focus as the UK navigates all the issues surrounding Brexit.
7th January 2019
Tackling temperature excursions
Saddam Huq, global QA senior manager, Distribution & Cold Chain, at GlaxoSmithKline, speaks to PharmaTimes about temperature excursions and managing the associated risks on a global scale.
7th January 2019
Digital Therapeutics will transform Pharma and healthcare industries in 2019. Here’s how.
The traditional pharma industry is eyeing the rise of Digital Therapeutics as patient outcomes fast become the only metric to sweat over. Their combined effect is setting the scene for a radical transformation of the industry. Its survival as a dominant force in shaping healthcare will depend on how it responds.
2nd January 2019
Winning the battle for tech talent
Excitement around the transformative potential of AI and machine learning continues to build. Companies will need to adapt their individual offers to draw in AI specialists, but as an industry UK pharma should also continue to champion itself and the unique career advantages it holds for the best and brightest researchers.
12th December 2018
NIHR welcomes Life Sciences Sector Deal 2
Professor Chris Whitty, chief scientific adviser for the Department of Health and Social Care (DHSC), on the role of the NIHR and the promise of the government's second sector deal for the life sciences industry.
6th December 2018
Adapting to the challenge
Mark Toms, chief scientific officer at Novartis Pharmaceuticals UK, looks at how to address the challenges of recruiting for Alzheimer’s prevention studies.
6th December 2018
Orphan drug development and the urgent need for a new approach
There are around 7,000 rare diseases for which there currently exists no authorised or satisfactory method of treatment, highlighting a vast area of unmet need, and yet the clinical development of orphan drugs is still fraught with many practical challenges.
5th December 2018
The escalating pharma counterfeit problem
The escalating counterfeit problem in the pharmaceutical industry is causing damage to companies and putting lives at risk.
5th December 2018
Recognition where it’s due: the Access to Medicines Index and the pharma industry
The 2018 Access to Medicines Index is encouraging and shows that the pharmaceutical industry continues to do more to improve access to medicine in low- and middle-income countries.
3rd December 2018
Innovate or bust: why the “i” word is key to tackling global health pandemics
Could innovation (true and urgent cross-sector partnership-led innovation) really be the key to tackling the world’s major global health pandemics?
28th November 2018
